Outlook Therapeutics (OTLK) Faces a Binary FDA Verdict on July 29 — With a Reverse-Split-and-Dilution Vote Stacked in Front of It
OTLK faces a binary July 29 FDA verdict on the first approved ophthalmic bevacizumab for wet AMD after a senior FDA body overruled three rejections — but its confirmatory trial missed its primary endpoint, and a reverse-split-and-dilution vote lands the next day.
On Wednesday, July 15, Outlook Therapeutics (NASDAQ: OTLK) closed at $1.56, down roughly 9.5% on the day, on volume near 9.6 million shares. The move is noise. What sits underneath it is not. This is a roughly $189 million company — about 120.9 million shares outstanding, a 52-week range of $0.16 to $3.39 — standing days from a binary July 29 FDA decision that either validates a decade of work or turns the lights out.
This is not the OTLK from our earlier coverage. The whole Complete Response Letter saga has resolved into a single, dated event — with a capital-structure vote stacked right in front of it.
The catalyst — a PDUFA date on July 29, 2026
On June 16, the FDA accepted Outlook's resubmitted Biologics License Application for ONS-5010 / LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for wet (neovascular) age-related macular degeneration. The agency classified it as a Class 1 review and set a PDUFA target action date of July 29, 2026.
If approved, ONS-5010 would become the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States — a branded, on-label version of a drug retina specialists already inject off-label by the millions. CEO Bob Jahr, who took the top job in July 2025, framed the acceptance as the FDA reviewing labeling — his words, "the final step toward potential approval."
Why this cycle is genuinely different
Every prior swing at this target ended in rejection. There have been three Complete Response Letters — August 2023 (manufacturing and evidence), August 2025 (efficacy), and December 30, 2025 (insufficient confirmatory evidence). Each time, the FDA's review division said the effectiveness case was not made.
Then something rare happened. Outlook took the December rejection to a Formal Dispute Resolution — an internal appeal that goes over the head of the division that keeps saying no. On May 26, 2026, the FDA's Office of New Drugs — a level senior to those reviewers — granted the appeal, concluding that the pivotal NORSE TWO trial, together with confirmatory evidence, establishes substantial evidence of effectiveness, and that no additional clinical trials are required. That is the agency's own senior body overruling its line reviewers. In three prior cycles the science itself was in dispute. Now the FDA has, at its highest relevant level, said the science clears the bar.
There is a real-world proof point behind the paper: the same drug is already approved and selling in Europe. The European Commission granted marketing authorization in May 2024 and the UK's MHRA followed in July 2024, with commercial launches underway in Germany, the UK, and Austria. A wet-AMD approval is not theoretical for this molecule — it exists on two other regulators' books.
But there is a second front — and it cuts the other way
Here is the part the momentum crowd chasing the cashtag this morning is skating past. The very next day — Thursday, July 16 — Outlook's shareholders vote on a package that tells you exactly how fragile the balance sheet is: authorization for a reverse stock split (a ratio anywhere from 1-for-10 to 1-for-50), an increase in authorized shares from 260 million to 600 million, and additional warrant issuance. The delisting scare has, for now, eased: after a February bid-price deficiency notice, Outlook regained Nasdaq compliance on June 26, 2026, having held above $1.00 for ten straight sessions — so the reverse split reads as standby insurance, not an emergency. The teeth of this vote are the other two items: the jump in authorized shares and the warrant issuance are the machinery of dilution.
So an investor at $1.56 is exposed to two events at once, on nearly the same calendar: a binary drug approval on July 29, and a capital-structure problem — the dilution needed to fund a launch — that has to be solved regardless of what the FDA says. Approval without capital is survival on hard terms. Capital without approval is a crushing raise into a falling stock. The two-front setup — and what the stock likely does in each of the four paths that matter — is what almost no one on the retail stream has laid out.
The rest of this briefing is for paid members: the approval-versus-dilution decision tree, the NORSE EIGHT problem the FDA had to look past, the reverse-split-and-dilution mechanics, and four scenario-by-scenario price zones — distributions, never calls.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.